Online citations, reference lists, and bibliographies.
← Back to Search

Sulfiredoxin‐1 Is A Promising Novel Prognostic Biomarker For Hepatocellular Carcinoma

Qianwen Rao, Shi-Long Zhang, Mengzhou Guo, F. Yuan, Jialei Sun, F. Qi, Li‐Shun Wang, Biwei Yang, J. Xia
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Identifying novel prognostic biomarkers for hepatocellular carcinoma (HCC) and then, develop an effective individualized treatment strategy remain extremely warranted. The prognostic role of sulfiredoxin‐1(SRXN1), an antioxidant enzyme, remains unknown in HCC. This study aimed to explore the prognostic implications of SRXN1 in HCC patients after partial hepatectomy. The expression of SRXN1 in HCC and normal tissue were analyzed using the patients from the public databases and Zhongshan Hospital. The Cox regression, Kaplan‐Meier survival analysis, and time‐dependent receiver operating characteristic curves were performed to identify the predictive role of SRXN1 expression on HCC patients. A prognostic nomogram based on SRXN1 expression was constructed and validated to further confirm the predictive power of SRXN1 as a prognostic biomarker. Finally, functional enrichment analysis and protein‐protein interaction network analysis of SRXN1 and its associated genes were conducted. The results showed that SRXN1 was upregulated in HCC samples compared with the normal liver tissues. Patients with SRXN1 upregulation had shorter survival time. SRXN1 overexpression was significantly correlated with advanced clinicopathological parameters. The prognostic nomogram based on SRXN1 expression was proved to be more accurate than routine staging systems for the prediction of overall survival. Protein‐protein interaction network analysis demonstrated the first neighbor genes of SRXN1 mainly participated in response to oxidative stress. In brief, SRXN1 could be a prognostic biomarker for the management of HCC.
This paper references
10.1056/NEJM197211092871923
Alpha-fetoprotein in acute viral hepatitis.
T. Akeyama (1972)
10.1016/s0015-6264(78)80335-6
Hepatocellular carcinoma.
D. Woodfield (1986)
10.7326/0003-4819-107-4-526
Oxygen radicals and human disease.
C. Cross (1987)
10.1002/1097-0142(19891115)64:10<2117::AID-CNCR2820641024>3.0.CO;2-7
Elevations in serum alpha‐fetoprotein levels in patients with chronic hepatitis B
A. D. Di Bisceglie (1989)
Cellular adaptation in the origin and development of cancer.
E. Farber (1991)
10.1016/0014-5793(94)01368-B
Persistent oxidative stress in cancer
S. Toyokuni (1995)
10.1038/35030140
Superoxide dismutase as a target for the selective killing of cancer cells
P. Huang (2000)
10.1016/J.GENE.2004.04.032
Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells.
J. Boonstra (2004)
10.1158/0008-5472.CAN-06-0484
A novel role for human sulfiredoxin in the reversal of glutathionylation.
V. Findlay (2006)
10.1200/JCO.2006.07.1290
Are nomograms better than currently available stage groupings for bladder cancer?
C. Sternberg (2006)
10.1111/j.1600-0463.2007.apm_514.x
Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies
P. Karihtala (2007)
10.1038/nprot.2008.211
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
(2008)
10.1056/NEJMoa0708857
Sorafenib in advanced hepatocellular carcinoma.
J. Llovet (2008)
10.1093/nar/gkn923
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
D. Huang (2008)
10.1002/pmic.201000486
Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells
B. Seliger (2011)
10.1002/hep.24104
Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol‐induced oxidative injury in mouse liver
S. Bae (2011)
10.1083/jcb.201102095
Signal transduction by reactive oxygen species
T. Finkel (2011)
10.3904/kjim.2011.26.3.304
Nuclear factor E2-related factor 2 Dependent Overexpression of Sulfiredoxin and Peroxiredoxin III in Human Lung Cancer
Y. Kim (2011)
10.2165/11592590-000000000-00000
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
A. Montero (2011)
10.1016/j.humpath.2011.05.024
Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer.
Heta Merikallio (2012)
10.1158/0008-5472.CAN-12-1474
Genetic polymorphisms and protein expression of NRF2 and Sulfiredoxin predict survival outcomes in breast cancer.
J. Hartikainen (2012)
10.1021/bi301006w
Sulfiredoxin redox-sensitive interaction with S100A4 and non-muscle myosin IIA regulates cancer cell motility.
R. R. Bowers (2012)
10.1016/j.freeradbiomed.2012.05.020
Role of sulfiredoxin as a regulator of peroxiredoxin function and regulation of its expression.
W. Jeong (2012)
10.1007/s12032-013-0786-2
Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma
Qi-kai Sun (2013)
10.1002/jnr.23218
Sulfiredoxin‐1 protects PC12 cells against oxidative stress induced by hydrogen peroxide
Qiong‐ya Li (2013)
10.1093/carcin/bgu035
Tumor promoter-induced sulfiredoxin is required for mouse skin tumorigenesis.
Lisha Wu (2014)
10.1016/j.redox.2014.09.002
Role of sulfiredoxin in systemic diseases influenced by oxidative stress
Asha Ramesh (2014)
10.1136/gutjnl-2013-306627
Hepatocellular carcinoma: clinical frontiers and perspectives
J. Bruix (2014)
10.1016/j.canlet.2015.07.002
The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.
M. Mishra (2015)
10.1016/S1470-2045(14)71116-7
Nomograms in oncology: more than meets the eye.
V. Balachandran (2015)
10.1158/1541-7786.MCR-15-0240
Sulfiredoxin Promotes Colorectal Cancer Cell Invasion and Metastasis through a Novel Mechanism of Enhancing EGFR Signaling
H. Jiang (2015)
10.1371/journal.pone.0166231
High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma
Jianfeng Wang (2016)
10.1007/s10549-016-4013-7
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients
A. Lánczky (2016)
10.1016/j.freeradbiomed.2015.12.023
Sulfiredoxin inhibitor induces preferential death of cancer cells through reactive oxygen species-mediated mitochondrial damage.
Hojin Kim (2016)
10.1016/j.neo.2017.05.002
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses1
D. Chandrashekar (2017)
10.1155/2017/4698167
TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma
B. Fu (2017)
10.1016/j.humpath.2017.09.002
Prognostic implication of NQO1 overexpression in hepatocellular carcinoma.
Lijuan Lin (2017)
10.1177/1010428317700410
GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
Ting Liu (2017)
10.3390/ijms18050917
Sulfiredoxin May Promote Cervical Cancer Metastasis via Wnt/β-Catenin Signaling Pathway
K. Lan (2017)
UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia
DS Chandrashekar (2017)
10.1016/j.jtho.2018.05.037
Development and Validation of a Nomogram Prognostic Model for SCLC Patients
Shidan Wang (2018)
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
10.1098/rsos.181006
Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma
O. Menyhárt (2018)
10.1002/hep.30467
Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma
Derek Lee (2019)
10.7150/jca.29769
High GCLC level in tumor tissues is associated with poor prognosis of hepatocellular carcinoma after curative resection
Jialei Sun (2019)
10.1155/2020/2148562
Sulfiredoxin as a Potential Therapeutic Target for Advanced and Metastatic Prostate Cancer
C. N. Barquilha (2020)
10.1016/J.CANLET.2020.02.008
NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Hoi-Wing Leung (2020)



Semantic Scholar Logo Some data provided by SemanticScholar